Physician profile
Daniel Manesh
NPI 1780283234
$2,816.85
in general payments reported to CMS, 2019-2025
27 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $845 · 2023: $164 · 2024: $619 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $559.51 | 2021-2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $233.47 | 2025 | |
| Acadia Pharmaceuticals INC | $219.61 | 2024-2025 | Daybue |
| Smith+Nephew, INC. | $195.57 | 2022 | |
| Inspire Medical Systems, INC. | $149.92 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $139.21 | 2023-2024 | Uzedy, Austedo Xr |
| Calliditas Therapeutics US INC. | $121.33 | 2025 | Tarpeyo |
| Kyowa Kirin, INC. | $120.56 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $119.95 | 2022 | |
| Veryan Medical Incorporated | $119.63 | 2022 | |
| Novo Nordisk INC | $103.16 | 2025 | Rybelsus, Ozempic, Wegovy |
| Lucid Diagnostics INC. | $102.14 | 2022 | |
| Amgen INC. | $100.37 | 2025 | Repatha, Krystexxa, Prolia |
| Travere Therapeutics, INC. | $85.91 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.15 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $50.48 | 2023-2024 | Ingrezza |
| Mallinckrodt Hospital Products INC. | $46.11 | 2025 | Acthar |
| Lilly USA, LLC | $44.78 | 2025 | Mounjaro, Zepbound, Jardiance |
| Kerecis Limited | $39.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.86 | 2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $26.22 | 2024 | Abilify Asimtufii |
| Angiodynamics, INC. | $24.89 | 2025 | Auryon Laser System 100-120 Vac |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.18 | 2024 | Caplyta |
| Lundbeck LLC | $22.55 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $20.05 | 2025 | Lokelma |
| Ardelyx, INC. | $16.32 | 2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $14.56 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Manesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.